XML 48 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes the disaggregation of revenue by nature:
 Year Ended December 31,
Dollars in millions202420232022
Net product sales$46,778 $43,778 $44,671 
Alliance revenues479 608 742 
Other revenues1,043 620 746 
Total Revenues$48,300 $45,006 $46,159 
Schedule of Revenue by Major Customers
Gross revenue to the three largest pharmaceutical wholesalers in the U.S. as a percentage of U.S. gross revenues was as follows:
 Year Ended December 31,
 202420232022
McKesson Corporation34 %33 %32 %
Cencora, Inc.
29 %29 %25 %
Cardinal Health, Inc.22 %23 %21 %
Reconciliation of Gross Product Sales to Net Product Sales
The following table summarizes GTN adjustments:
 Year Ended December 31,
Dollars in millions202420232022
Gross product sales$83,671 $73,679 $69,633 
GTN adjustments(a)
Charge-backs and cash discounts(11,510)(9,144)(7,469)
Medicaid and Medicare rebates(16,551)(13,411)(11,362)
Other rebates, returns, discounts and adjustments(8,832)(7,346)(6,131)
Total GTN adjustments(36,893)(29,901)(24,962)
Net product sales$46,778 $43,778 $44,671 
(a)    Includes reductions of provisions for product sales made in prior periods resulting from changes in estimates of $159 million in 2024, $134 million in 2023, and $229 million in 2022.
Disaggregation of Revenue by Product and Region
The following table summarizes the disaggregation of revenue by product and region:
 Year Ended December 31,
Dollars in millions202420232022
Growth Portfolio
Opdivo$9,304 $9,009 $8,249 
Orencia3,682 3,601 3,464 
Yervoy2,530 2,238 2,131 
Reblozyl1,773 1,008 717 
Opdualag928 627 252 
Breyanzi747 364 182 
Camzyos602 231 24 
Zeposia566 434 250 
Abecma406 472 388 
Sotyktu246 170 8 
Krazati126 — — 
Augtyro38 1 — 
Cobenfy
10 — — 
Other Growth products(a)
1,605 1,211 1,092 
Total Growth Portfolio22,563 19,366 16,757 
Legacy Portfolio
Eliquis13,333 12,206 11,789 
Revlimid5,773 6,097 9,978 
Pomalyst/Imnovid3,545 3,441 3,497 
Sprycel1,286 1,930 2,165 
Abraxane875 1,004 811 
Other Legacy products(b)
925 962 1,162 
Total Legacy Portfolio25,737 25,640 29,402 
Total Revenues$48,300 $45,006 $46,159 
United States34,105 31,210 31,500 
International13,199 13,097 13,825 
Other(c)
996 699 834 
Total Revenues$48,300 $45,006 $46,159 
(a)    Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.
(b)    Includes other mature brands.
(c)    Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations.